All In MedTech

FDA Clearance Tracker · P040045

VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 20, 2005 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Dec 20, 2005

Approved

Time to decision

400 days

Received Nov 15, 2004. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P040045
Device name
VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER
Applicant location
Jacksonville, FL
Received
Nov 15, 2004
Decided
Dec 20, 2005
Decision
Approved
Supplements
143 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER. THE DEVICE IS INDICATED FOR USE AS FOLLOWS: THE VISTAKON (SENOFILCON A) SOFT CONTACT LENS (SPHERICAL) IS INDICATED FOR THE OPTICAL CORRECTION OF REFRACTIVE AMETROPIA (MYOPIA AND HYPEROPIA) IN PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WHO HAVE 1.00D OR LESS OF ASTIGMATISM. THE VISTAKON (SENOFILCON A) MULTIFOCAL SOFT CONTACT LENS IS INDICATED FOR THE OPTICAL CORRECTION OF DISTANCE AND NEAR VISION IN PRESBYOPIC, PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WHO MAY HAVE 0.75D OF ASTIGMATISM OR LESS. THE VISTAKON (SENOFILCON A) TORIC SOFT CONTACT LENS IS INDICATED FOR THE OPTICAL CORRECTION OF VISUAL ACUITY IN PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES THAT ARE HYPEROPIC OR MYOPIC AND MAY HAVE 10.00D OF ASTIGMATISM OR LESS. THE VISTAKON (SENOFILCON A) MULTIFOCAL-TORIC SOFT CONTACT LENS IS INDICATED FOR THE OPTICAL CORRECTION OF DISTANCE AND NEAR IN PRESBYOPIC PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WHO MAY HAVE 10.00D OF ASTIGMATISM OR LESS. THE VISTAKON (SENOFILCON A) UV BLOCKING SOFT CONTACT LENS HELP PROTECT AGAINST TRANSMISSION OF HARMFUL UV RADIATION TO THE CORNEA AND INTO THE EYE. EYE CARE PROFESSIONALS MAY PRESCRIBE THE LENSES EITHER FOR SINGLE-USE DISPOSABLE WEAR OR FREQUENT/PLANNED REPLACEMENT WEAR WITH CLEANING, DISINFECTION AND SCHEDULED REPLACEMENT. WHEN PRESCRIBED FOR FREQUENT/PLANNED REPLACEMENT WEAR THE LENSES MAY BE CLEANED AND DISINFECTED USING A CHEMICAL DISINFECTION SYSTEM ONLY. VISTAKON (SENOFILCON A) CONTACT LENSES MAY BE PRESCRIBED FOR DAILY WEAR AND EXTENDED WEAR FOR UP TO 6 NIGHTS/7 DAYS OF CONTINUOUS WEAR. IT IS RECOMMENDED THAT THE CONTACT LENS WEARER FIRST BE EVALUATED ON A DAILY WEAR SCHEDULE. IF SUCCESSFUL, THEN A GRADUAL INTRODUCTION OF EXTENDED WEAR CAN BE FOLLOWED AS DETERMINED BY THE PRESCRIBING EYE CARE PROFESSIONAL.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LPM. The earliest in FDA's data is N16895, decided Mar 18, 1971.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Vistakon, Division of Johnson & Johnson Vision Car

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.